trapelo IN THE NEWS

Read what others around the country are reporting about us

March  3, 2020  |  OncLive
Using Trapelo to Maintain Molecular Testing Guidelines for Ovarian Cancer

Lori Brisban, VP of precision medicine at Texas Oncology talks about the ovarian cancer beta trial they are conducting with community oncologists and how Trapelo is helping one of the  largest oncology practices in the U.S. standardize molecular testing guidelines.

February 23, 2020  |  OncLive
Dr. Paulson on the Importance of Biomarker Testing in Oncology

R. Steven Paulson, MD, physician, president and chairman at Texas Oncology, discusses the importance of molecular testing in the era of precision medicine in oncology.

January 17, 2020  |  OncLive
Utility of Trapelo to Increase Molecular Testing Rates

Lori Brisban, VP of precision medicine at Texas Oncology, talks about how Trapelo helps  oncologists keep up-to-date with the latest guidelines and know which molecular test is the right test for the right patient and the right tumor type. 

October 2, 2019  |  OncLive
Technology Advances Aid Treatment Decisions for Community Oncologists

Molecular testing has become an imperative step in the treatment decision-making process for oncologists, and new technologies and assays are emerging to further help identify tumor abnormalities and at the right time.

For example, Trapelo is a novel single-technology platform with the ability to automatically update with treatment guidelines from the National Comprehensive Cancer Network (NCCN) and more to assist community oncologists with deciding on the optimal therapeutic path for their patients, explained Lori Brisbin.

“Only 30% of patients are being tested for precision medicine. If we don't test…then that is not a treatment option for them,” said Brisbin, vice president of precision medicine at Texas Oncology. “[The goal of Trapelo] is to advise on whom to test.”

In an interview during the 2019 OncLive® State of the Science Summit™ on Precision Medicine, Brisbin discussed using these types of technology platforms in precision medicine as well as the role of liquid biopsies.

August 12, 2019  |  BioWorld MedTech
Data seen as replacing policy as coverage tool for precision medicine

The era of big data might still be in its infancy, but payers are already dealing with a deluge of bits and bytes that threatens to overwhelm their ability to keep up with recent developments in medical science. Clynt Taylor, CEO of Intervention Insights Inc., of Burlington, Mass., told BioWorld MedTech that payers are starting to see the light when it comes to reacting to data that suggest a shift in coverage policy, but that over time, payers will replace those fixed policies with a data-driven approach that adapts to patients' needs in real time.

July, 2019  |  HIT Like A Girl Podcast
An interview with Janine Morales, PhD, Senior Director Clinical Knowledge Systems
In this podcast, Janine Morales, PhD of Intervention Insights shares her career path as a woman in Health IT and how her company’s real-time, evidence-supported technology platform helps oncologists, practices, molecular labs, and payers make the most appropriate decisions for cancer patients.
Janine Morales Interview - Unknown Artist
00:00 / 00:00
July 26, 2019  |  Healthcare IT News
Physicians are key to making precision medicine investments pay off

As the practice of tailoring technology-driven treatment plans for each patient takes hold, physicians are being asked to make more specific decisions than ever before.
 

Finding the best care for a patient can be a constantly moving target. The number of stakeholders, the constant advance of new information and treatment options and the nuanced demands of different payers make for a maze of complexities to navigate. In the field of oncology, for example, nobody but a specialist could be expected to keep up with the growing wealth of knowledge in the treatment of individual cancers.

Yet most patients are treated by general oncologists who may not be abreast of every best course of action for specific conditions. These practices might not know which treatments a patient could be pre-approved for, or which payers are most likely to compensate and for what. As the practice of tailoring precision medicine plans for each patient takes hold, physicians are being asked to make more specific treatment decisions than ever before.

"You have labs, you have payers, you have providers and you have pharma – and they’re all interested in what the doctor is about to do with a patient," said Clynt Taylor, CEO of Intervention Insights, which makes a tool called Trapelo that helps streamline treatment and payment options.

June 21, 2019  |  American Journal of Managed Care
Removing the Barriers to Improve the Use of Diagnostic Tests for Precision Cancer Care

Currently, the number of patients who are actually utilizing precision cancer care treatments is small, but it is growing fast. As that happens, physicians will need to get comfortable with ordering the right tests, explained Clynt Taylor, chief executive officer of Intervention Insights, and Lee Newcomer, MD, formerly of UnitedHealth Group.

May 10, 2019  |  Journal of Clinical Pathways 
Intervention Insights Offers Platform for Streamlining Molecular Testing, Prior Authorization Processes
At the Association of Community Cancer Centers Annual Meeting and Cancer Center Business Summit, the Journal of Clinical Pathways' Zachary Bessette spoke with Clynt Taylor, CEO of Intervention Insights, about a new platform designed to cater to the needs of providers, molecular labs, and payers in the testing and ordering of appropriate targeted therapies for patients with cancer.
April 29, 2019 |  Big3Bio 
Spotlight: Precision Medicine Decision-Making Support for Oncologists
Big3Bio’s Marie Daghlian spoke with Intervention Insights CEO Clynt Taylor to find out how Trapelo came to be and how it fits in the evolving precision medicine landscape.
April 26, 2019  |  Health Innovation Matters Podcast
Precision Medicine in Oncology with Clynt Taylor
Host Robin Smith, MD chats with Clynt Taylor, CEO of Intervention Insights, about the difficulties in finding the latest treatment options for his father’s particular subset of cancer; why we can’t ignore the payer, and how the Trapelo platform marries clinical trial data and lab tests to help figure out the optimal treatment for the patient.
April 17, 2019  |  BioIT World Conference and Expo
Trapelo wins "Best of Show: Patient-focused software" at BioIT
April 15, 2019  |  MD+DI Digital Health
Tackling Precision Medicine with a New Kind of Decision Support
March 13, 2019  |  PR Web
Intervention Insights CEO Clynt Taylor to Present at Boston Oncology Investor Conference
February 1, 2019  |  Genome Web
Precision Medicine Platform for Oncology Aims to Streamline Molecular Testing, Therapy Decision-Making
December 17, 2018  |  Health Data Management
Decision support tool helps City of Hope docs find answers quicker
December 5, 2018  |  IT News Online 
First Application of Trapelo™ Clinical Decision Support Platform Enhances
Precision Medicine Program at World-renowned Comprehensive Cancer Center
November 19, 2018  |  Becker's ASC Review   
Intervention Insights CEO: 3 ways to reform prior authorization processes
November 1, 2018  |  Becker's ASC Review
Intervention Insights CEO: 3 ways prior authorization burdens patients & practices
October 31, 2018  |  Becker's ASC Review
Intervention Insights CEO: 4 issues with traditional prior authorization processes
icon-linkedin.png
TwitterIcon_Bird_Only2.png
YouTube_Icon_Only_Orange_Trans.png

PHONE  617.250.7572

FAX  888.972.5991

EMAIL information@trapelohealth.com

800 District Ave, Suite 310
Burlington, MA 01803

Google Map »

Copyright 2020 Trapelo Health. All rights reserved. Privacy Policy